TetraLogic Pharma -69% after birinapant study shows no clinical benefit

• TetraLogic Pharmaceuticals (OTC:TLOG) -68.8% AH after announcing that its Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes failed to demonstrate any clinical benefit over a placebo.
• In a separate study, an interim analysis of a randomized Phase 2 clinical study of SHAPE, TLOG's proprietary topical HDAC inhibitor, eight of 34 patients showed a clinical benefit to treatment as assessed by CAILS, the primary endpoint.